New drug tested for tough HPV cancers that Won't quit
NCT ID NCT05826275
Summary
This early-stage trial tested a new drug called TGN-S11 in people with HPV-related cancers that had returned, resisted treatment, or spread. The main goal was to find the highest safe dose. The study involved 28 participants whose cancers had progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV ASSOCIATED CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10128, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
-
Yale University
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.